Skip to content
HowShorted

CRISPR Therapeutics AG short interest in 2021

In 2021, CRISPR Therapeutics AG's disclosed short interest ran from 5.15% of shares outstanding on 15 Jan 2021 to 10.52% on 31 Dec 2021, a change of +5.37 percentage points. The year's high was 10.65% on 15 Dec 2021 and its low 3.06% on 15 Jul 2021, averaging 5.48% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 5.09 days on 31 Dec 2021. Full history: CRISPR Therapeutics AG.

Cite this page
Plain
Wikipedia
BibTeX

By year: 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for CRISPR Therapeutics AG in 2021

2021 in figures

Start of year
5.15% (15 Jan 2021)
End of year
10.52% (31 Dec 2021)
Change
+5.37 pp
High
10.65% (15 Dec 2021)
Low
3.06% (15 Jul 2021)
Average
5.48%
Highest days to cover
5.09 (31 Dec 2021)
SEC filings marked
8

Every report in 2021

CRISPR Therapeutics AG short interest in 2021
SettlementShort interestDays to coverFilings since previous
15 Jan 20215.15%1.49
29 Jan 20214.17%1.41
12 Feb 20214.04%1.49
26 Feb 20214.98%1.7210-K filed, results (8-K)
15 Mar 20215.60%1.66
31 Mar 20215.91%3.05
15 Apr 20215.63%3.99
30 Apr 20214.56%2.2710-Q filed, results (8-K)
14 May 20215.11%2.41
28 May 20214.38%3.69
15 Jun 20214.44%3.33
30 Jun 20214.24%1.65
15 Jul 20213.06%1.78
30 Jul 20213.39%2.3210-Q filed, results (8-K)
13 Aug 20213.85%2.23
31 Aug 20213.89%3.40
15 Sep 20214.16%3.58
30 Sep 20213.50%2.63
15 Oct 20216.33%2.21
29 Oct 20217.33%4.23
15 Nov 20217.65%4.1210-Q filed, results (8-K)
30 Nov 20219.07%4.93
15 Dec 202110.65%4.63
31 Dec 202110.52%5.09

See also: CRISPR Therapeutics AG's full history · most shorted US stocks of 2021 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.